Scarica l'app Stockscreener
47.43
2.47%
1.1422
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BMY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$46.29
Aprire:
$46.255
Volume 24 ore:
16.49M
Relative Volume:
1.17
Capitalizzazione di mercato:
$101.69B
Reddito:
$47.64B
Utile/perdita netta:
$5.42B
Rapporto P/E:
17.76
EPS:
2.67
Flusso di cassa netto:
$13.09B
1 W Prestazione:
+0.86%
1M Prestazione:
-1.75%
6M Prestazione:
-16.13%
1 anno Prestazione:
+14.85%
Intervallo 1D:
$46.17
$48.26
Intervallo di 1 settimana:
$46.16
$48.26
Portata 52W:
$39.35
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
Nome
Bristol Myers Squibb Co
Settore
Industria
Telefono
(609) 252-4621
Indirizzo
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Confronta BMY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
47.42 | 101.69B | 47.64B | 5.42B | 13.09B | 2.67 |
|
LLY
Lilly Eli Co
|
778.03 | 724.64B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
155.72 | 376.43B | 89.33B | 21.81B | 18.57B | 8.99 |
|
NVO
Novo Nordisk Adr
|
69.83 | 352.49B | 43.59B | 15.04B | 10.74B | 3.3766 |
|
ABBV
Abbvie Inc
|
189.59 | 334.73B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
123.06 | 234.21B | 53.22B | 12.86B | 14.85B | 6.39 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
| 2025-04-22 | Iniziato | Piper Sandler | Overweight |
| 2024-12-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-13 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | Downgrade | Citigroup | Buy → Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-07-29 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-03-11 | Downgrade | Societe Generale | Buy → Hold |
| 2024-02-06 | Downgrade | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-11-15 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-02 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-10-27 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-07-10 | Iniziato | SVB Securities | Market Perform |
| 2023-06-28 | Iniziato | Daiwa Securities | Outperform |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-01-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-11-18 | Iniziato | Credit Suisse | Neutral |
| 2022-10-10 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-09-14 | Downgrade | Berenberg | Buy → Hold |
| 2022-06-03 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | Ripresa | Morgan Stanley | Underweight |
| 2021-12-17 | Iniziato | Goldman | Buy |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-11-01 | Downgrade | Argus | Buy → Hold |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-04-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | Aggiornamento | Truist | Hold → Buy |
| 2020-11-16 | Aggiornamento | Societe Generale | Hold → Buy |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-11-06 | Downgrade | Gabelli & Co | Buy → Hold |
| 2020-10-19 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-09-29 | Iniziato | Berenberg | Buy |
| 2020-07-28 | Iniziato | Raymond James | Outperform |
| 2020-04-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | Downgrade | Societe Generale | Buy → Hold |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-01-06 | Ripresa | Citigroup | Buy |
| 2019-12-13 | Aggiornamento | Argus | Hold → Buy |
| 2019-11-22 | Ripresa | Morgan Stanley | Equal-Weight |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-08-14 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | Iniziato | Goldman | Buy |
| 2019-05-20 | Downgrade | Argus | Buy → Hold |
| 2019-05-03 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-05-03 | Ripresa | JP Morgan | Overweight |
| 2019-01-15 | Aggiornamento | Societe Generale | Sell → Buy |
| 2018-10-22 | Downgrade | Citigroup | Buy → Neutral |
Mostra tutto
Bristol Myers Squibb Co Borsa (BMY) Ultime notizie
Bristol Myers Squibb (BMY) Collaborates on Alzheimer's Drug Deve - GuruFocus
Bristol-Myers (NYSE:BMY) Squibb Dividend Update Reflects Steady Healthcare NYSE Composite - Kalkine Media
Bristol-Myers Squibb (NYSE:BMY) Declares US$0.62 Common and US$0.50 Preferred Dividends - Yahoo
BioNTech and Bristol Myers Squibb Collaborate on BNT327, a PD-L1xVEGF-A Bispecific Antibody for Tumor Treatment - geneonline.com
Bristol Myers Squibb to present positive new data on lymphoma treatment - Pharmafile
Bristol Myers Squibb (BMY) Loses Key Executive to Climb Bio | BM - GuruFocus
Bristol Myers Squibb (BMY) Loses Key Executive to Climb Bio | BMY Stock News - GuruFocus
Global Drugmakers Tap Chinese Biotech for Novel Cancer Therapies - Caixin Global
Bristol Myers Squibb declares quarterly dividend of $0.62 per share By Investing.com - Investing.com Nigeria
Bristol Myers Squibb Announces Dividend - marketscreener.com
Bristol-Myers Expands in Cancer Care With $1.35B OncoACP3 Deal - Insider Monkey
Editas Medicine Is Great. Here's Why You Shouldn't Buy It. - The Motley Fool
BioNTech and Bristol Myers Squibb Partner to Develop PD-L1xVEGF-A Bispecific Antibody for Cancer Therapy - geneonline.com
Bristol Myers Squibb Presents Promising Blood Cancer Drug Data at EHA Congress - MSN
Bristol Myers Squibb (BMY) Shares Cross 5% Yield Mark - Nasdaq
Myocardial Infarction Market Is Booming So Rapidly 2025-2032 - openPR.com
Vanguard Health Care Fund's Strategic Moves: A Closer Look at Bristol-Myers Squibb Co - Yahoo Finance
Bristol-Myers Squibb (BMY) Announces Positive Data From the Pivotal Phase 3 POETYK PsA-1 Trial - MSN
Bristol Myers Squibb (BMY) Achieves Strong Results with Breyanzi in Lymphoma Study - GuruFocus
Bristol Myers: positive phase 2 data in lymphoma - MarketScreener
Bristol Myers (BMY) Reports Promising Results from Lymphoma Stud - GuruFocus
Schizophrenia Drugs Market Size, Share & Forecast 2025 | Major - openPR.com
Bristol-Myers Squibb (BMY) Stock Analysis: Healthcare Giant with a 14.77% Potential Upside - DirectorsTalk Interviews
Business development leadership team - Bristol Myers Squibb
BioNTech and Bristol Myers Squibb Partner to Develop PD-L1xVEGF-A Bispecific Antibody for Cancer Treatment - geneonline.com
Rockland Trust Co. Sells 20,035 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Jim Cramer on Bristol Myers: “We Need to See That Stock Back Up at $60” - Insider Monkey
BioNTech and Bristol Myers Squibb Partner to Develop Bispecific Antibody Targeting PD-L1 and VEGF-A for Tumor Treatment - geneonline.com
Bristol-Myers Squibb’s SWOT analysis: stock outlook amid Cobenfy growth and pipeline potential - Investing.com
Bristol Myers gets a key strategist with 'Team Shibs'; Idorsia to change CEOs after it 'hit a reset button' - Endpoints News
Bristol Myers (BMY) Showcases Promising New Data on Targeted Pro - GuruFocus
Bristol-Myers Promotes Attorney To Lead Corporate Affairs - Law360
BioNTech and Bristol Myers Squibb Partner to Develop BNT327 Antibody Targeting PD-L1 and VEGF-A Pathways in Tumors - geneonline.com
Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu Compared with Placebo in Adults with Psoriatic Arthritis - marketscreener.com
Bristol-Myers stock holds steady as Cantor maintains neutral rating By Investing.com - Investing.com South Africa
BMY Reports Positive Data on Sotyktu From Arthritis Study - TradingView
Bristol Myers Squibb promotes Wendy Bartie to lead corporate affairs - PR Week UK
Bristol Myers: new data to be presented in hematology - marketscreener.com
Bristol-Myers stock holds steady as Cantor maintains neutral rating - Investing.com
Bristol Myers Squibb presents protein degradation data at EHA By Investing.com - Investing.com India
Bristol Myers Squibb presents protein degradation data at EHA - Investing.com
Bristol Myers Squibb Sets Q2 2025 Earnings Date: Key Financial Results Coming July 31 - Stock Titan
Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025 - The Joplin Globe
Bristol Myers Squibb (BMY) Exceeds Market Returns: Some Facts to Consider - MSN
Bristol-Myers Squibb (NYSE:BMY) Reports Positive Phase 3 Trial Results For Sotyktu - Yahoo Finance
Bristol Myers at Goldman Sachs Conference: Strategic Insights on Growth - Investing.com Australia
Bristol Myers bolsters radiopharma portfolio with PhiloChem deal - BioPharma Dive
Transcript : Bristol-Myers Squibb Company Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 10 - MarketScreener
Bristol Myers (BMY) Sees Promising Results for Sotyktu in Phase 3 Trial - GuruFocus
BioNTech and Bristol Myers Squibb Collaborate on PD-L1xVEGF-A Bispecific Antibody for Tumor Treatment - geneonline.com
Bristol-Myers Squibb To Present At Goldman Sachs Global Conference; Webcast At 10:00 AM ET - Nasdaq
Bristol Myers Squibb Co Azioni (BMY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Bristol Myers Squibb Co Azioni (BMY) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Hickey Benjamin | President, RayzeBio Org. |
May 09 '25 |
Sale |
38.01 |
97 |
3,702 |
0 |
| Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. |
Apr 25 '25 |
Buy |
47.58 |
4,250 |
202,215 |
83,513 |
| Shanahan Karin | EVP, Glob. Prod. Dev. & Supply |
Apr 01 '25 |
Option Exercise |
0.00 |
3,306 |
0 |
15,489 |
| Plenge Robert M | EVP, Chief Research Officer |
Mar 10 '25 |
Option Exercise |
0.00 |
11,255 |
0 |
20,148 |
| Meyers Gregory Scott | EVP, Chief Digital & Tech Off. |
Mar 10 '25 |
Option Exercise |
0.00 |
23,150 |
0 |
26,937 |
| Shanahan Karin | EVP, Glob. Prod. Dev. & Supply |
Mar 10 '25 |
Option Exercise |
0.00 |
20,423 |
0 |
22,339 |
| Lenkowsky Adam | EVP, Chief Commercial Officer |
Mar 10 '25 |
Option Exercise |
0.00 |
16,684 |
0 |
20,017 |
| Poole Ahn Amanda | EVP, Chief People Officer |
Mar 10 '25 |
Option Exercise |
0.00 |
7,164 |
0 |
8,546 |
| LEUNG SANDRA | EVP, General Counsel |
Mar 10 '25 |
Option Exercise |
0.00 |
48,718 |
0 |
386,496 |
| Hoch Lynelle | President, Cell Therapy Org. |
Mar 10 '25 |
Option Exercise |
0.00 |
7,446 |
0 |
7,920 |
1.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):